Breaking News Instant updates and real-time market news.

NVS

Novartis

$85.24

-0.02 (-0.02%)

, JNJ

Johnson & Johnson

$139.86

0.38 (0.27%)

14:14
09/17/18
09/17
14:14
09/17/18
14:14

Americans deserve to know lowest drug price at their pharmacy, Trump says

President Donald Trump tweeted: "Americans deserve to know the lowest drug price at their pharmacy, but "gag clauses" prevent your pharmacist from telling you! I support legislation that will remove gag clauses and urge the Senate to act. #AmericanPatientsFirst" Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens Boots Alliance (WBA) and Rite Aid (RAD). Reference Link

NVS

Novartis

$85.24

-0.02 (-0.02%)

JNJ

Johnson & Johnson

$139.86

0.38 (0.27%)

GSK

GlaxoSmithKline

$39.31

0.3 (0.77%)

PFE

Pfizer

$43.00

0.03 (0.07%)

AZN

AstraZeneca

$37.61

0.16 (0.43%)

SNY

Sanofi

$43.91

0.09 (0.21%)

RHHBY

Roche

$0.00

(0.00%)

LLY

Eli Lilly

$106.02

0.265 (0.25%)

MRK

Merck

$70.25

0.27 (0.39%)

BMY

Bristol-Myers

$61.29

0.6 (0.99%)

CVS

CVS Health

$77.94

1.03 (1.34%)

WBA

Walgreens Boots Alliance

$70.41

0.13 (0.18%)

RAD

Rite Aid

$1.30

0.005 (0.39%)

  • 17

    Sep

  • 20

    Sep

  • 26

    Sep

  • 01

    Oct

  • 01

    Oct

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

  • 11

    Oct

  • 15

    Oct

  • 17

    Oct

  • 20

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 11

    Jan

  • 28

    Jan

  • 16

    Feb

  • 22

    Mar

  • 28

    Apr

NVS Novartis
$85.24

-0.02 (-0.02%)

09/11/18
EXAN
09/11/18
UPGRADE
EXAN
Neutral
Novartis upgraded to Neutral from Underperform at Exane BNP Paribas
09/11/18
SBSH
09/11/18
UPGRADE
SBSH
Buy
Novartis upgraded to Buy from Neutral at Citi
Citi upgraded Novartis to Buy from Neutral. Exane BNP Paribas also upgraded the shares this morning to Neutral.
09/11/18
09/11/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Buy from Hold at Canaccord with analyst Camilo Lyon saying he believes Nike has regained its footing and is marching back to form following two years of a soft product cycle, margin compression, and market share declines. 2. Novartis (NVS) upgraded to Buy from Neutral at Citi and to Neutral from Underperform at Exane BNP Paribas. 3. Darden (DRI) upgraded to Buy from Neutral at Goldman Sachs while Bloomin' Brands (BLMN) was upgraded to Neutral from Sell. 4. South Jersey Industries (SJI) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Turnure saying the company's "superior" growth potential is coming into focus while its shares trade at a discount to peers. 5. Snap (SNAP) upgraded to Outperform from Neutral at Wedbush with analyst Michael Pachter noting that decelerating growth trends, fierce competition for user mindshare and advertiser dollars, and a history of being hugely unprofitable have kept him on the sidelines, but recent management changes and improved execution have led him to update his outlook. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/17/18
FBCO
09/17/18
NO CHANGE
Target $26
FBCO
Neutral
Teva price target raised to $26 from $23 at Credit Suisse
Credit Suisse analyst Vamil Divan reiterated a Neutral rating on Teva Pharmaceutical (TEVA) and raised his price target to $26 after the company said it received FDA approval for Ajovy, a key pipeline drug for migraine prevention and approval of a quarterly dosing for the drug, providing an important point of differentiation relative to competitors from Eli Lilly (LLY) and Amgen (AMGN)/Novartis (NVS). In a research note to investors, Divan says Friday's approval provides Teva with an important potential growth driver as it looks to overcome the challenges it faces with U.S. generics, Copaxone and its large debt load, and expects a "strong" positive reaction in the stock. Divan says he will look to see how Teva commercializes Ajovy in the coming months before becoming more constructive on the stock's longer-term outlook.
JNJ Johnson & Johnson
$139.86

0.38 (0.27%)

08/27/18
MSCO
08/27/18
NO CHANGE
MSCO
Equal Weight
Portola may be up 'somewhat' on Xarelto trial failure, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted the failure of Johnson & Johnson's (JNJ)MARINER study, which was examining Xarelto, a competing anticogulant to Portola's (PTLA) BevyxXa. MARINER's failure to demonstrate a statistically significant result of reducing symptomatic VTE or death due to VTE is expected by Harrison to send Portola shares up "somewhat," but he believes most investors had already lowered their expectations for the BevyxXa franchise after the Q2 report, making the impact modest. He maintains an Equal Weight rating on Portola shares, which are up 3% to $29 per share in early trading.
09/14/18
WELS
09/14/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson price target raised to $160 from $150 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target for Johnson & Johnson to $160 after the company hosted an investor call to provide an update on its Pharmaceuticals business. The analyst heard no strategic change to the business saying J&J maintains focus on its six key therapeutic areas and remains agnostic to the source of innovation. While the company did not provide 2019 guidance, management's tone came across as confident in the business outlook, Biegelsen tells investors in a research note. He keeps an Outperform rating on Johnson & Johnson.
08/27/18
08/27/18
UPGRADE
Target $34

Neutral
Portola Pharmaceuticals upgraded to Neutral as MARINER sinks at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Portola Pharmaceuticals (PTLA) to Neutral from Underperform after Johnson & Johnson (JNJ)/Bayer (BAYRY) presented disappointing data for Xarelto in the acute medically ill population at ESC. The analyst notes that the data avoids a worst case scenario for Portola's Bevyxxa by essentially removing a potentially strong competitor, but does put the pressure on Portola to successfully change medical practice on its own, without help from a larger player such as Johnson & Johnson. Divan also raised his price target on Portola's shares to $34 from $28.
08/27/18
WBLR
08/27/18
NO CHANGE
WBLR
Outperform
Mariner failure removes potential Portola competition, says William Blair
William Blair analyst Matt Phipps says that while the failure of Johnson & Johnson's (JNJ) Mariner trial removes potential competition Portola Pharmaceuticals' (PTLA) Bevyxxa, which is positive, "significant work" is still needed to gain adoption of Bevyxxa in the United States. As such, the Mariner results do not significantly alter the near-term headwinds for Bevyxxa, Phipps tells investors in a research note. The analyst believes getting beyond the Mariner presentation allows investors to focus on the opportunity for Andexxa, which he still thinks is "significant." He points out that Portola remains on track to file the prior approval supplement for the second-generation manufacturing process of Andexxa in the coming days, which would provide sufficient supply for 1,000 hospitals in the United States and expansion into Europe. Phipps keeps an Outperform rating on Portola Pharmaceuticals, which is up 5% to $29.60 in premarket trading.
GSK GlaxoSmithKline
$39.31

0.3 (0.77%)

08/16/18
08/16/18
DOWNGRADE

Hold
AstraZeneca downgraded to Hold following outperformance at Jefferies
As previously reported, Jefferies analyst Ian Hilliker downgraded AstraZeneca (AZN) to Hold from Buy citing valuation following the stock's outperformance since he upgraded it in March. Hilliker has raised his price target on AstraZeneca to 6,200p, but notes that this only leaves about 8% of further upside. Following results for the Q2 period, Hilliker said Novartis (NVS) remains his top European Pharmaceuticals pick, followed by Roche (RHHBY) and GlaxoSmithKline (GSK) in third place.
07/25/18
WELS
07/25/18
NO CHANGE
WELS
Market Perform
Even minor delays can hurt Mylan's generic Advair opportunity, says Wells Fargo
After GlaxoSmithKline (GSK) reported U.S. Advair sales declined 43% at constant currency in Q2, Wells Fargo analyst David Maris commented on the read-through to the generic Advair opportunity being pursued by Mylan (MYL). Given the substantial declines branded Advair faces, he said that "even minor delays" can continue to hurt the potential generic opportunity, adding that he has not seen or been notified of any updates from Mylan on Advair since the company was notified in early June that the FDA planned to issue an official Complete Response Letter related to its application. Maris keeps a Market Perform rating on Mylan shares.
08/30/18
08/30/18
DOWNGRADE

GlaxoSmithKline downgraded to Hold from Buy at Liberum
Liberum analyst Roger Franklin downgraded GlaxoSmithKline to Hold while raising his price target for the shares to GBP 17 from GBP 16.30. The analyst believes the company's improved research and development is now priced into the shares and he sees less upside going forward.
08/15/18
RBCM
08/15/18
NO CHANGE
RBCM
Outperform
RBC says Gilead weakness on CMO leaving, Glaxo data a buying opportunity
RBC Capital analyst Brian Abrahams believes Gilead's (GILD) weakness is potentially due to data from GlaxoSmithKline's (GSK) ATLAS trial and last night's announcement of the departure of its CMO. However, he does not see either as a major fundamental concern and would use the weakness in Gilead shares as a buying opportunity. Feedback he has received from doctors is that injectables like Glaxo's could be used in a select number of patients, but he does not see a major impact on Gilead's HIV franchise near- or long-term from this product, Abrahams said. On the CMO departure, the analyst said that the company clarified that this is "completely unrelated" to the recently-announced CEO transition, so he does not see this reflecting any major structural issue. Abrahams keeps an Outperform rating on Gilead shares, which are down over 3% to $74.82 in afternoon trading.
PFE Pfizer
$43.00

0.03 (0.07%)

09/06/18
BMOC
09/06/18
NO CHANGE
Target $47
BMOC
Outperform
Pfizer price target raised to $47 from $44 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Pfizer to $47 and kept his Outperform rating, citing the company's Tafamidis potential prospects of $3.5B or more in sales by 2027. The analyst notes that Transthyretin Amyloid Cardiomyopathy, or ATTR-CM, is a "fatal, under-diagnosed heart disease with no approved treatments", but the new method of diagnosis could ramp up from 1% to 20%, supporting the "robust efficacy" with "benign safety" offered by the company's treatment. Arfaei further contends that Pfizer's 3.5% dividend yield and 14-times forward earnings multiple make the stock attractive.
09/06/18
BOFA
09/06/18
NO CHANGE
Target $92
BOFA
Buy
Exact Sciences price target raised to $92 post Pfizer deal at BofA/Merrill
BofA/Merrill analyst Derik de Bruin said Exact Sciences (EXAS) co-promotion agreement for Cologuard with Pfizer (PFE) adds significant "marketing muscle" to the company's strong fundamental story. The deal will help Exact Sciences penetrate healthcare systmes and allow the company to increase its advertising and promotional spect through better rates by utilizing Pfizer's purchasing power, the analyst wrote in a note to investors. de Bruin reiterates his Buy rating on Exact Sciences and increased his price target to $92 from $68 on shares.
09/11/18
BARD
09/11/18
NO CHANGE
Target $85
BARD
Outperform
Exact Sciences price target raised to $85 from $74 at Baird
Baird analyst Catherine Ramsey Schulte raised her price target on Exact Sciences (EXAS) to $85 from $74 citing increased confidence in its partnership with Pfizer (PFE). She sees several different potential outcomes given different assumptions for Pfizer rep productivity and order rate increases. Schulte reiterated her Outperform rating on Exact Sciences shares.
09/12/18
ADAM
09/12/18
NO CHANGE
Target $87
ADAM
Buy
Exact Sciences price target raised to $87 from $72 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Exact Sciences (EXAS) as he updated his model to include the contribution of Pfizer (PFE) reps. Massaro, who believes the company is well positioned to expand its business and he raised his estimates, reiterated his Buy rating on Exact Sciences shares.
AZN AstraZeneca
$37.61

0.16 (0.43%)

09/05/18
PIPR
09/05/18
NO CHANGE
Target $48
PIPR
Overweight
Biohaven deal with AstraZeneca enhances leadership, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says Biohaven Pharmaceutical (BHVN) has licensed a Phase III-ready central nervous system asset from AstraZeneca (AZN) that appears to have $500M-plus potential and "further broadens the company's pipeline." Based on his follow-up with management, the analyst believes the upfront cash payment is modest and that the Phase III trial will be efficient and require an estimated additional spend of $20M. Van Buren thinks the deal is an "attractively structured, efficient and opportunistic" that enhances Biohaven's leadership in CNS drug development. He keeps an Overweight rating on the shares with a $48 price target.
09/17/18
PIPR
09/17/18
NO CHANGE
Target $35
PIPR
Neutral
Piper sees Astra's Lynparza as 'much cleaner' than Tesaro's Zejula
Piper Jaffray analyst Christopher Raymond reiterates a Neutral rating and $35 price target on Tesaro (TSRO) after analyzing a year's worth of adverse event reporting as captured by FDA's Adverse Event Reporting System database, which he obtained through a Freedom of Information Act request. The analyst, while cautioning that the database "likely contains inaccuracies and is far from perfect," is "struck by how much cleaner" AstraZeneca's (AZN) Lynparza appears versus Tesaro's Zejula and Clovis Oncology's (CLVS) Rubraca. Further, Raymond is also surprised that Zejula's adverse events rates do not appear to have decreased in any meaningful way year-over-year, despite Tesaro's active down-dosing efforts. Since the analyst thinks PARPi differentiation remains largely around safety, he lowered his Zejula estimates in 2019 and beyond. Lynparza is likely to maintain the upper hand, Raymond tells investors in a research note.
09/06/18
HCWC
09/06/18
NO CHANGE
Target $11
HCWC
Buy
H.C. Wainwright impressed by Checkpoint Therapeutics' first clinical data
H.C. Wainwright analyst Joseph Pantginis says Checkpoint Therapeutics' (CKPT) first clinical data in its history "did not disappoint." The data show a "significant clinical benefit" from CK-101 treatment, Pantginis tells investors in a research note. With these safety and efficacy data in hand, Checkpoint's CK-101 may show competitive clinical advantages versus approved EGFR therapies, including AstraZeneca's Tagrisso, at least in the non-small-cell lung carcinoma indication, the analyst contends. He's "impressed" with the data and notes that Checkpoint management has confirmed its intention to move into a pivotal study in 2019 mimicking the Tagrisso Flaura study. Pantginis has a Buy rating on Checkpoint Therapeutics with an $11 price target.
09/14/18
ROTH
09/14/18
NO CHANGE
Target $33
ROTH
Buy
Roth Capital remains bullish on Stemline after AstraZeneca's Lumoxiti approved
Roth Capital analyst Jotin Marango said he had viewed the BLA review for AstraZeneca's (AZN) Lumoxiti for Hairy Cell Leukemia as a relative gauge of what might happen with Stemline's (STML) Elzonris given what he sees as the similarities between the agents. Lumoxiti's approval makes him more bullish on Stemline ahead of the Q1 of 2019 PDUFA date for Elzonris, said Marango, who raised his assumed probability of success for its BLA to 90% from 75%. He raised his price target on Stemline shares to $33 from $30 and keeps a Buy rating on the stock.
SNY Sanofi
$43.91

0.09 (0.21%)

09/10/18
BOFA
09/10/18
UPGRADE
BOFA
Buy
Sanofi upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Graham Parry upgraded Sanofi to Buy from Neutral saying the company is approaching an inflection in growth from new products, mainly Dupixent, atopic, dermatitis, while diabetes becomes less of a headwind. Parry believes sales and earnings growth will accelerate to 7% from 4% in through 20-2023E and views valuation as undervaluing growth.
09/10/18
MSCO
09/10/18
INITIATION
Target $72
MSCO
Overweight
MyoKardia initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Jeffrey Hung initiated MyoKardia (MYOK) at Overweight with a $72 price target, stating that the obstructive hypertrophic cardiomyopathy Phase 2 data for its lead program, mavacamten, were "robust" and the fact that the company is partnered with Sanofi (SNY) gives him incremental confidence. He expects a mavacamten launch in oHCM in early 2022 and peak U.S. sales for the drug of greater than $1.3B.
09/14/18
LSCM
09/14/18
NO CHANGE
Target $90
LSCM
Buy
Apple Watch more likely a positive for BioTelemetry, says Lake Street
After spending time with Joe Capper and Heather Getz, CEO and CFO of BioTelemetry (BEAT), Lake Street analyst Brooks O'Neil senses that Apple's (AAPL) Watch Series 4, which includes a built-in electrocardiogram, is more likely a positive for BioTelemetry "than a buzzer sounding a flat-line for the company's future." BioTelemetry remains the leading cardiac monitoring company and this is likely to continue for the foreseeable future, O'Neil tells investors in a research note. He points out the company has a partnership with Apple in cardiac monitoring and with Sanofi (SNY) and Alphabet (GOOG) in diabetes. The analyst's guesses that its partnership is one element giving BioTelemetry management comfort in evaluating the role Apple might play in the company's future. O'Neil reaffirms a Buy rating on the shares with a $90 price target.
09/13/18
STFL
09/13/18
INITIATION
Target $127
STFL
Buy
AnaptysBio resumed with a Buy at Stifel
Stifel analyst Derek Archila resumed coverage of AnaptysBio (ANAB) with a Buy rating and $127 price target, stating that he is positively biased heading into etokimab's Phase 2a results for severe eosinophilic asthma, given his view on the strong rationale for the inhibition of IL-33, etokimab's meaningful reduction of eosinophils seen in an earlier Phase 2a study, and the success of Regeneron (REGN) and Sanofi's (SNY) Dupixent.
RHHBY Roche
$0.00

(0.00%)

09/10/18
09/10/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Inogen (INGN) downgraded to Buy from Strong Buy at Needham with analyst Mike Matson citing the potential for slower growth as tougher comps start in the second half of 2018, along with a tighter level of competition from Resmed (RMD) and valuation following the 122% year-to-date run-up in the stock price. 2. UnitedHealth (UNH) and Anthem (ANTM) were downgraded to Neutral from Buy at Citi. 3. Constellation Brands (STZ) downgraded to Hold from Buy at SunTrust with analyst William Chappell saying the company's recent $4B investment in Canopy Growth may "keep a cloud" over the stock for the next few quarters, as there is "little certainty" in the deal's revenue or profit potential. 4. Darden (DRI) downgraded to Neutral from Outperform at Baird with analyst David Tarantino citing its recent strength and recommends a more disciplined approach to buying in the short-term as many restaurant names begin to look extended. 5. Roche (RHHBY) downgraded to Neutral from Buy at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/10/18
BOFA
09/10/18
DOWNGRADE
BOFA
Neutral
Roche downgraded to Neutral from Buy at BofA/Merrill
09/17/18
OPCO
09/17/18
NO CHANGE
Target $400
OPCO
Outperform
Roche's AD updates provide favorable read-through for Biogen, says Oppenheimer
Oppenheimer analyst Jay Olson says he remain bullish on Biogen (BIIB), telling investors in a research note that he believes Roche's (RHHBY) Alzheimer's disease updates provide a favorable read-through for Biogen's own Alzheimer's disease portfolio. Among the takeaways from Roche's pipeline update are the importance of a reduction in amyloid, confidence in dose escalation, epidemiology estimate and reimbursement commentary. Olson, who has an Outperform rating and $400 price target on Biogen, says he believes shares are undervalued based on his view that the company's leadership position in neuroscience should deliver long-term growth.
09/13/18
CANT
09/13/18
NO CHANGE
Target $36
CANT
Overweight
Cantor boosts Corbus target to Street-high $36 after Roche study 'fell short'
Cantor Fitzgerald analyst Elemer Piros raised his price target for Corbus Pharmaceuticals to a Street-high $36 following abstracts from the American College of Rheumatology meeting, which is taking place in October. Among the abstracts, Phase 3 data from Roche's (RHHBY) Phase 3 systemic sclerosis study with competitive agent tocilizumab fell short on its primary endpoint in modified Rodnan skin score, Piros tells investors in a research note partially titled "Lenabasum's Gain, Following Tocilizumab's Loss." The analyst believes the results establish Corbus' lenabasum, in Phase 3 now for systemic sclerosis, as the" only compelling treatment option for patients in this rare and life-threatening disease." Further, Additionally, Piros believes lenabasum's resolution of inflammatory activity was further validated in an assessment of interferon response in patients with dermatomyositis. The analyst reiterates an Overweight rating on the shares. Corbus Pharmaceuticals in afternoon trading is up 7.5c to $5.28.
LLY Eli Lilly
$106.02

0.265 (0.25%)

07/25/18
BMOC
07/25/18
NO CHANGE
Target $90
BMOC
Market Perform
Eli Lilly price target raised to $90 from $80 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Eli Lilly to $90, saying the company is doing an "excellent" job in managing its mature franchises and should finish 2018 at the top end of its guidance. The analyst also believes that the company can achieve its 2015-20 annual revenue growth target of 5% or more. Arfaeil keeps his Market Perform rating however, noting that its valuation reflects the opportunities around Tanezumab, migraine and Alzheimer's franchises while also pointing to the "underappreciated" risks around its insulins franchise.
07/25/18
07/25/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Spotify (SPOT) downgraded to Hold from Buy at Pivotal Research with analyst Jeffrey Wlodarczak citing valuation. 2. Eli Lilly (LLY) downgraded to Hold from Buy at Berenberg with analyst Laura Sutcliffe saying the company reported "very good" Q2 results and its sales growth is built on the "solid proposition" of Trulicity, but the company is in the process of re-stocking its late-stage pipeline both internally and via deals. 3. Walmart (WMT) downgraded to Hold from Accumulate at Gordon Haskett with analyst Chuck Grom saying he thinks there are few near-term catalysts on the horizon and the margin outlook is not as transparent following a period of improvement and stabilization, and expects shares to be range bound for the balance of the year. 4. Hormel Foods (HRL) downgraded to Underperform from Neutral at Mizuho with analyst Jeremy Scott saying "volatile and retreating" pork margins bring rising risks to Hormel's earnings. 5. BJ's Wholesale (BJ) downgraded to Accumulate from Buy at Gordon Haskett with analyst Chuck Grom citing share strength following the IPO. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/07/18
STFL
08/07/18
INITIATION
Target $30
STFL
Buy
Alder Biopharmaceuticals initiated with a Buy at Stifel
Stifel analyst Paul Matteis initiated coverage of Alder BioPharmaceuticals with a Buy rating and $30 price target, calling it an attractive, differentiated "pure play" within the migraine antiCGRP prevention market. While Matteis acknowledges it "won't be easy" for Alder to compete with Amgen (AMGN), Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), he believes the unique profile of eptinezumab remains underappreciated and may allow it to capture meaningful, above consensus share of a large, emerging drug category.
MRK Merck
$70.25

0.27 (0.39%)

06/14/18
MSCO
06/14/18
NO CHANGE
Target $68
MSCO
Overweight
Merck Q2 estimates lowered below consensus at Morgan Stanley
Morgan Stanley analyst David Risinger cut his Q2 revenue estimate for Merck by 1% to $10.1B, which he notes is below the consensus view of $10.3B, and lowered his Q2 EPS estimate by 6% to 97c. This is below the consensus view of $1.03, which he argues "needs to come down." The two key drivers were lowering his estimates for Keytruda in the U.S. due to a more gradual ramp in first-line lung cancer patients and the negative impact of hedging, which he sees being similar to, but less pronounced, than in Q1. He lowered his full-year EPS view by only 1%, however, which puts it 2% below consensus. Risinger keeps an Overweight rating and $68 price target on Merck shares.
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
08/23/18
MSCO
08/23/18
NO CHANGE
Target $74
MSCO
Overweight
Merck price target raised to $74 from $68 at Morgan Stanley
Morgan Stanley analyst David Risinger maintained an Overweight rating on Merck and raised his price target to $74 from $68, citing his expectation for operating leverage to become more visible in 2019 and pipeline progress to improve perception about prospects in the face of Januvia generics in January 2023. Looking ahead, Risinger projects Merck's 5-year CAGR from 2018-2023 for revenue growth of 3% and EPS growth of 8%. Risinger says he believes the primary driver of major pharma stock performance in recent months is "defensive rotation." Looking ahead, the analyst says to watch for U.S. pricing perception drivers in the coming months that could impact pharma stock performance, including potential additional HHS action on drug rebates, November election results and manufacturer communication and action on U.S. list prices by early January.
BMY Bristol-Myers
$61.29

0.6 (0.99%)

08/08/18
ATLE
08/08/18
UPGRADE
ATLE
Neutral
Bristol-Myers upgraded to Neutral from Underweight at Atlantic Equities
08/08/18
08/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dean Foods (DF) upgraded to Hold from Sell at Deutsche Bank. 2. Plantronics (PLT) upgraded to Buy from Neutral at Sidoti with the firm citing attractive valuation. 3. CarGurus (CARG) upgraded to Outperform from Market Perform at JMP Securities and to Outperform from Sector Perform at RBC Capital. 4. Bristol-Myers (BMY) upgraded to Neutral from Underweight at Atlantic Equities. 5. Floor & Decor (FND) upgraded to Buy from Hold at Loop Capital with analyst Anthony Chukumba saying the company continues to post the "best relative performance in the flooring retailing industry." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/06/18
MSCO
09/06/18
NO CHANGE
Target $63
MSCO
Equal Weight
Bristol-Myers' TYK2 inhibitor may be underappreciated asset, says Morgan Stanley
Morgan Stanley analyst David Risinger said that Phase 2 data on Bristol-Myers' oral TYK2 inhibitor BMS-986165 will be presented at the EADV meeting on Wednesday September 12, adding that it could be an underappreciated asset if it offers better efficacy than other oral drugs and is safer. To his knowledge, no JAK inhibitors are currently being developed for psoriasis, Risinger noted. The analyst, who said 986165 "theoretically has blockbuster potential," maintains an Equal Weight rating on Bristol shares as further Opdivo lung newsflow is awaited.
09/12/18
FBCO
09/12/18
NO CHANGE
FBCO
Neutral
Bristol-Myers' TYK2 efficacy looks better than Otezla, says Credit Suisse
After Bristol-Myers (BMY) presented Phase 2 data for its oral TYK2 inhibitor, BMS-986165, in moderate-to-severe psoriasis at the EAVD meeting, Credit Suisse analyst Vamil Divan said he believes the "robust" data are very encouraging for the ongoing Phase 3 studies. BMS-986165 achieved PASI 75 response rates that are better than what was demonstrated by Celgene's (CELG) Otezla and the safety profile "appears reasonable," Divan tells investors. While BMS-986165 could be highly competitive clinically against other oral treatments, the crowded psoriasis market remains a tough one for new products, added the analyst, who keeps a Neutral rating on Bristol-Myers shares.
CVS CVS Health
$77.94

1.03 (1.34%)

09/17/18
RBCM
09/17/18
NO CHANGE
Target $101
RBCM
Outperform
CVS Health price target raised to $101 from $90 at RBC Capital
RBC Capital analyst George Hill raised his price target on CVS Health (CVS) to $101 and kept his Outperform rating, citing the increased visibility of the company's merger with Aetna (AET) after its recent comments that it expects the deal to close in early Q4. The analyst also points to "de-risked" CVS investment thesis as it pertains to pharmacy benefit managers rebates and the much higher relative multiples for managed care companies, even though he warns that investors may still be spooked by any potential steps that the White House takes to drive prescription drug prices lower. Hill notes however that the latest government funding bill pulled the text that required drug companies to disclose prices in their ads, implying that the political will to change status quo may be limited.
08/23/18
08/23/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. ROSENBLATT BOOSTS AMD PRICE TARGET TO STREET HIGH: Rosenblatt analyst Hans Mosesmann raised his price target for AMD (AMD) shares to $30 from $27. Mosesmann's new price target represents the high among Wall Street sell-side analysts. Following the meetings, Mosesmann has renewed conviction in AMD's multi-year double digit growth profile. Further, he's impressed by the analysis investors are doing in the name after years of disregard. AMD is up 4.1% in late morning trading. CANTOR CUTS AETNA TO NEUTRAL: Cantor Fitzgerald analyst Steven Halper downgraded Aetna (AET) to Neutral from Overweight with a price target of $202. The stock now trades at just a 4.6% discount to the implied CVS Health (CVS) acquisition value of about $207 per share, Halper said. He believes the narrowed deal spread reflects an increased likelihood of regulatory approval. Halper cites limited potential upside for his downgrade of Aetna to Neutral. NIELSEN UPGRADED TO NEUTRAL AT GOLDMAN: Goldman Sachs analyst George Tong upgraded Nielsen Holdings (NLSN) to Neutral and raised his price target for the shares to $25 from $20. With activist Elliott Management pushing for a sale and increased deal activity in the Information Services sector, Tong sees increased likelihood of Nielsen being involved in a transaction. His upgrade to Neutral and price target increase come after the analyst incorporated a potential takeover into his model. Nielsen is up 3.3% in late morning trading. IMPERIAL SEES SUBSCRIBER UPSIDE FOR NETFLIX: Imperial Capital analyst David Miller believes Netflix's (NFLX) experiment with ending billing through Apple's (AAPL) app store in 33 countries outside the U.S. likely implies upside to its Q3 international subscriber guidance. The analyst said he has a tough time believing that Netflix would "experiment" with billing infrastructure mid-quarter if it did not believe that its international subscriber levels were trending ahead of guidance. As such, Miller raised his Q3 international subscriber estimate to 4.46M from 4.35M. He kept an Outperform rating on Netflix with a $494 price target. TARGET GETS UPGRADE AND DOWNGRADE: Target (TGT) was upgraded to Outperform from Market Perform at Telsey Advisory, and downgraded to Peer Perform from Outperform at Wolfe Research.
08/27/18
RBCM
08/27/18
NO CHANGE
Target $94
RBCM
Outperform
Express Scripts price target raised to $94 from $90 at RBC Capital
RBC Capital analyst George Hills raised his price target on Express Scripts (ESRX) to $94 and kept his Outperform rating, citing the shareholders' "blessing" of the merger with Cigna (CI). The analyst notes that even though the regulators are yet to rule on the deal, he expects the merger to close by the end of the year and has a positive view of the "vertical consolidation thesis" for the company. Hill adds that the chance of a Department of Justice challenge to the merger is small in light of the seemingly clear path of the CVS (CVS) - Aetna (AET) merger, but if regulators do seek concessions, he expects the necessary divestitures to be small.
08/22/18
CANT
08/22/18
DOWNGRADE
Target $202
CANT
Neutral
Cantor downgrades Aetna to Neutral on limited potential upside
Cantor Fitzgerald analyst Steven Halper downgraded Aetna (AET) to Neutral from Overweight with a price target of $202. The stock now trades at just a 4.6% discount to the implied CVS Health (CVS) acquisition value of about $207 per share, Halper tells investors in a research note. He believes the narrowed deal spread reflects an increased likelihood of regulatory approval. The two companies should be able to find a remedy to satisfy regulatory concerns, the analyst contends. Halper cites limited potential upside for his downgrade of Aetna to Neutral.
WBA Walgreens Boots Alliance
$70.41

0.13 (0.18%)

09/10/18
LOOP
09/10/18
NO CHANGE
Target $2
LOOP
Hold
Fred's sells pharmacy files to Walgreens for 'good valuation,' says Loop Capital
Loop Capital analyst Andrew Wolf noted that Fred's (FRED) announced that Walgreens (WBA) will acquire pharmacy prescription files and related pharmacy inventory of 185 Fred's stores located across 10 Southeastern states subject to regulatory approval. The deal values the prescript files at $165M, which the analyst views as a "good valuation" particularly since Walgreens will also acquire the associated pharmacy inventory for up to $36M. Wolf believes the strategic basis for Walgreens to pay this "solid" valuation for the prescription files from Fred's was fortified by its recent purchase of 1,932 Rite Aid (RAD) stores, many in the same Southeastern footprint as Fred's. The analyst reiterates a Hold rating and $2 price target on Fred's shares.
07/23/18
COWN
07/23/18
DOWNGRADE
COWN
Market Perform
Walgreens Boots Alliance downgraded to Market Perform from Outperform at Cowen
07/23/18
COWN
07/23/18
DOWNGRADE
Target $71
COWN
Market Perform
Walgreens Boots Alliance downgraded to Market Perform at Cowen
As reported previously, Cowen analyst Charles Ryhee downgraded Walgreens Boots Alliance to Market Perform from Outperform. The analyst views it as poorly positioned in the move toward value-based care and believes the ownership of, rather than a partnership with, an insurance company is necessary to realize the benefits of cost trend improvements. Ryhee lowered his price target to $71 from $77 on Walgreen's Boots Alliance shares.
07/23/18
07/23/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Papa John's (PZZA) downgraded to Sell from Hold at Stifel with analyst Chris O'Cull saying the outlook for Papa John's is "growing dimmer" after recent media reports indicated a "fraternal corporate culture." 2. Buckeye Partners (BPL) downgraded to Sell from Hold at SunTrust with analyst Tristan Richardson saying the latest negative action by Moody's was "quicker than expected" and may lead to a cut in the company's distribution. 3. Walgreens Boots Alliance (WBA) downgraded to Market Perform from Outperform at Cowen with analyst Charles Ryhee saying he views it as poorly positioned in the move toward value-based care and believes the ownership of, rather than a partnership with, an insurance company is necessary to realize the benefits of cost trend improvements. 4. General Electric (GE) downgraded to Hold from Buy at Argus with analyst John Eade saying that despite his expectations of a turnaround, Q2 results were a "step in the opposite direction" suggesting the company will struggle to meet its FY18 guidance. 5. Philip Morris (PM) downgraded to Hold from Buy at Societe Generale. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
RAD Rite Aid
$1.30

0.005 (0.39%)

08/16/18
DBAB
08/16/18
NO CHANGE
Target $1.6
DBAB
Hold
Rite Aid faces challenges ahead as standalone business, says Deutsche Bank
Deutsche Bank analyst Glen Santangelo maintained a Hold rating on Rite Aid but cut his price target to $1.60 from $2.25 after re-evaluating the company as a standalone business following the termination of the merger agreement with Albertsons. In a research note to investors, the analyst says he believes the outlook will continue to be weighed down by the challenges facing the retail pharmacy industry such as declining volume and reimbursement pressure, and thinks that the fundamental challenges ahead for Rite Aid will make it difficult for the company to find a sustainable growth path on a standalone basis.
09/06/18
09/06/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Rite Aid (RAD) reinstated with a Sell at Goldman Sachs. 2. Parker-Hannifin (PH) initiated with an Overweight at Barclays. 3. iRhythm (IRTC) initiated with a Buy at Chardan. 4. Sarepta (SRPT) initiated with an Outperform at Credit Suisse. 5. Xperi (XPER) initiated with a Buy at National Securities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/06/18
GSCO
09/06/18
INITIATION
Target $1
GSCO
Sell
Rite Aid reinstated with a Sell at Goldman Sachs
Goldman Sachs analyst Robert Jones reinstated Rite Aid (RAD) with a Sell and $1 price target following the merger termination with Albertsons. Jones said the now standalone company lacks necessary scale to effectively compete and negotiate with healthcare supply chain players.

TODAY'S FREE FLY STORIES

RHHBY

Roche

$0.00

(0.00%)

13:02
10/21/18
10/21
13:02
10/21/18
13:02
Hot Stocks
Genentech's Tecentriq, Abraxane combo demonstrates positive Phase III results »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

PFE

Pfizer

$44.50

0.48 (1.09%)

12:56
10/21/18
10/21
12:56
10/21/18
12:56
Hot Stocks
Pfizer presents overall survival data from PALOMA-3 trial of Ibrance »

Pfizer announced detailed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:52
10/21/18
10/21
12:52
10/21/18
12:52
Hot Stocks
Merck presents early data for STING agonist in advanced solid tumors/lymphomas »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:47
10/21/18
10/21
12:47
10/21/18
12:47
Hot Stocks
Dynavax's SD-101, Keytruda combo still shows 70% ORR in Advanced Melanoma »

Dynavax (DVAX) presented…

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

12:44
10/21/18
10/21
12:44
10/21/18
12:44
Hot Stocks
Exelixis announces results from data analysis of CABOSUN, METEOR trials »

Exelixis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 01

    Nov

  • 07

    Nov

  • 27

    Nov

  • 14

    Jan

AGEN

Agenus

$1.97

-0.025 (-1.26%)

12:39
10/21/18
10/21
12:39
10/21/18
12:39
Hot Stocks
Agenus presents clinical data on PD-1, CTLA-4 at ESMO 2018 »

Agenus presented updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

OMED

OncoMed

$2.47

-0.17 (-6.44%)

12:37
10/21/18
10/21
12:37
10/21/18
12:37
Hot Stocks
OncoMed announces interim phase 1b results for Navicixizumab, Paclitaxel combo »

OncoMed Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:34
10/21/18
10/21
12:34
10/21/18
12:34
Hot Stocks
ImmunoGen presents initial data from FORWARD II expansion cohort »

ImmunoGen (IMGN)…

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 02

    Nov

  • 11

    Jan

  • 16

    Feb

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

12:30
10/21/18
10/21
12:30
10/21/18
12:30
Hot Stocks
Opdivo, Yervoy combo shows promising results in advanced form of bladder cancer »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:26
10/21/18
10/21
12:26
10/21/18
12:26
Hot Stocks
Merck's Keytruda shows complete response rate of nearly 40% in high-risk NMIBC »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

12:18
10/21/18
10/21
12:18
10/21/18
12:18
Hot Stocks
Tesaro presents Phase 1 GARNET data of TSR-042 in MSI-H endometrial cancer »

Tesaro summarized updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 07

    Nov

UDR

UDR, Inc.

09:37
10/21/18
10/21
09:37
10/21/18
09:37
Downgrade
UDR, Inc. rating change at Evercore ISI »

UDR, Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 07

    Nov

AVB

AvalonBay

$178.01

1.725 (0.98%)

09:37
10/21/18
10/21
09:37
10/21/18
09:37
Downgrade
AvalonBay rating change  »

AvalonBay downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
Morgan Stanley China hardware analyst to hold analyst/industry conference call »

China Hardware Tech…

BIIB

Biogen

$319.85

-10.4 (-3.15%)

14:57
10/20/18
10/20
14:57
10/20/18
14:57
Conference/Events
Biogen to host conference call »

Chief Medical Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

14:13
10/20/18
10/20
14:13
10/20/18
14:13
Conference/Events
Selecta Biosciences to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

TROV

Trovagene

$1.12

-0.03 (-2.61%)

14:11
10/20/18
10/20
14:11
10/20/18
14:11
Conference/Events
Trovagene to host conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLS

Sellas Life Sciences

$1.56

-0.24 (-13.33%)

13:54
10/20/18
10/20
13:54
10/20/18
13:54
Conference/Events
Sellas Life Sciences to host conference call »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 07

    Nov

NVS

Novartis

$87.19

0.95 (1.10%)

13:50
10/20/18
10/20
13:50
10/20/18
13:50
Conference/Events
Novartis to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

UA

Under Armour

$16.79

-0.365 (-2.13%)

, UAA

Under Armour

$18.20

-0.42 (-2.26%)

12:43
10/20/18
10/20
12:43
10/20/18
12:43
Periodicals
Under Armour stock could triple, Barron's says »

Under Armour has had a…

UA

Under Armour

$16.79

-0.365 (-2.13%)

UAA

Under Armour

$18.20

-0.42 (-2.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 30

    Oct

  • 27

    Nov

  • 03

    Mar

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

, CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

12:37
10/20/18
10/20
12:37
10/20/18
12:37
Periodicals
Constellation Brands changing CEOs, not marijuana strategy, Barron's says »

Constellation Brands…

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 14

    Nov

CFG

Citizens Financial

$36.36

1.44 (4.12%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:33
10/20/18
10/20
12:33
10/20/18
12:33
Periodicals
Citizens Financial stock worth buying, Barron's says »

Citizens Financial (CFG)…

CFG

Citizens Financial

$36.36

1.44 (4.12%)

AAPL

Apple

$219.28

3.3 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.95

-1 (-0.65%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:26
10/20/18
10/20
12:26
10/20/18
12:26
Periodicals
Netflix emerged as winner in new way to rank big tech stocks risk, Barron's says »

A year ago,…

FB

Facebook

$153.95

-1 (-0.65%)

AAPL

Apple

$219.28

3.3 (1.53%)

AMZN

Amazon.com

$1,763.91

-7.54 (-0.43%)

NFLX

Netflix

$332.69

-14.02 (-4.04%)

GOOG

Alphabet

$1,096.41

8.51 (0.78%)

GOOGL

Alphabet Class A

$1,104.66

7.43 (0.68%)

DIS

Disney

$118.81

2.55 (2.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.